- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02281201
Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects
May 2, 2016 updated by: CSL Behring
An Open-label, Uncontrolled, Single-arm, Multicenter Phase IIIb Study to Assess the Efficacy and Safety of BE1116 in Japanese Subjects Receiving Vitamin K Antagonist Therapy With an Elevated INR and Either Acute Major Bleeding or a Requirement for Urgent Reversal of Vitamin K Antagonist Therapy for a Surgical or Invasive Medical Procedure
The purpose of this study is to evaluate efficacy and safety of a Prothrombin Complex Concentrate (PCC), BE1116.
BE1116 will be used for the rapid reversal of coagulopathy induced by vitamin K antagonists in Japanese subjects who require immediate correction of international normalized ratio (INR) due to a major bleed or emergency surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bunkyo
-
Sendagi, Bunkyo, Japan, 113-8603
- Nippon Medical School Hospital
-
-
Fukuoka
-
Chuo-ku, Fukuoka, Japan, 810-8563
- Kyushu Medical Center
-
-
Inzai
-
Kamagari, Inzai, Japan, 270-1694
- Nippon Medical School Chiba Hokusoh Hospital
-
-
Kurashiki
-
Miwa, Kurashiki, Japan, 710-0052
- Kurashiki Central Hospital
-
-
Osaka
-
Chuo-ku, Osaka, Japan, 540-0006
- Osaka National Hospital
-
Higashiosaka, Osaka, Japan, 577-0818
- Kinki University
-
Suita, Osaka, Japan, 565-0873
- National Cerebral and Cardiovascular Center
-
-
Sendai
-
Aoba-ku, Sendai, Japan, 980-8574
- Tohoku University Hospital
-
-
Shinjuku
-
Toyama, Shinjuku, Japan, 162-0052
- National Center for Global Health and Medicine
-
-
Suita
-
Yamadaoka, Suita, Japan, 565-0871
- Osaka University Hospital
-
-
Tokyo
-
Chuo, Tokyo, Japan, 104-8560
- St. Luke's International Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female Japanese subjects greater than or equal to 20 years
- Subjects currently on vitamin K antagonist (VKA) therapy
- INR greater than or equal to 2 within 3 hours before start of BE1116 infusion
- Urgent reversal of VKA therapy for a surgical or invasive medical procedure is required within 24 hours of the start of BE1116 infusion, or presentation with an acute major bleed
Exclusion Criteria:
- Subjects for whom administration of I.V. vitamin K and VKA withdrawal, alone, can adequately correct the subject's coagulopathy before the infusion of BE1116
- Subjects in whom lowering the INR to within the normal range is not a treatment goal
- Use of anticoagulants other than VKAs (or expected use within 1 day)
- Medical history for which PCCs are contraindicated
- History of thromboembolic event within 3 months of screening
- Congenital or acquired abnormality of hemostasis other than receipt of VKAs
- Administration of whole blood, plasma, plasma fractions, or platelets within 2 weeks prior to the start of BE1116 infusion
For subjects with intracranial hemorrhage (ICH):
- Glasgow Coma Score (GCS) < 7
- Intracerebral hematoma volume > 30 cm3 as assessed by computed tomography (CT) scan
- For subdural hematomas: maximum thickness ≥ 10 mm, midline shift ≥ 5 mm, or acute subdural hematomas (based on neurosurgeon review)
- For subarachnoid hemorrhage: any evidence of hydrocephalus, or Hunt and Hess Scale > 2, or concomitant subdural hematoma
- Infratentorial ICH location
- Epidural hematomas
- Intraventricular rupture of hemorrhage
- Requires surgical intervention
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: BE1116
Single intravenous (I.V.) infusion, dosage depending on baseline INR and body weight
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With a Rapid Reversal of VKA Effect
Time Frame: At baseline and at 30 minutes after the end of infusion
|
A rapid reversal of (Vitamin K antagonist) VKA effect is a reduction of the INR to ≤ 1.3 at 30 minutes after the end of infusion.
|
At baseline and at 30 minutes after the end of infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
45-Day All-cause Mortality
Time Frame: Until Day 45
|
Until Day 45
|
|
Percentage of Subjects Achieving Hemostatic Efficacy During Surgery
Time Frame: From the start of surgery/procedure until the end of surgery/procedure
|
Hemostatic efficacy is the binary endpoint of effective or non-effective hemostasis, where 'effective' is a hemostatic efficacy rating of "very good" or "satisfactory", and 'non-effective' is a hemostatic efficacy rating of "questionable" or "none".
|
From the start of surgery/procedure until the end of surgery/procedure
|
Percentage of Subjects Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed
Time Frame: Baseline CT scan, baseline haematology or the end of infusion, until 24 hours after the end of infusion
|
Hemostatic efficacy is the binary endpoint of effective or non-effective hemostasis, where 'effective' is a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' is a hemostatic efficacy rating of "poor/none".
|
Baseline CT scan, baseline haematology or the end of infusion, until 24 hours after the end of infusion
|
Increase in Plasma Levels of Factor (F)II, FVII, FIX, and FX, and Protein C and Protein S
Time Frame: Before infusion and up to 3 h after the start of infusion
|
The increase in plasma levels is assessed through response and in vivo recovery (IVR) of FII, FVII, FIX, FX, and protein C and protein S. The incremental IVR [(IU/dL)/(IU/kg)] is calculated as follows: (IU/dL activity rise in plasma)/(IU/kg body weight infused) = [maximum increase in component plasma level within 3 hours compared to pre-infusion (IU/dL)]/{[exact dose of component in drug administered (IU)]/[body weight (kg)]}.
|
Before infusion and up to 3 h after the start of infusion
|
Percentage of Subjects With INR Correction
Time Frame: From the start of infusion until INR correction, up to 24 hours after the end of infusion
|
The time taken from the start of infusion to INR correction (defined as an INR ≤ 1.3) is recorded.
The percentage of participants with INR correction is calculated.
|
From the start of infusion until INR correction, up to 24 hours after the end of infusion
|
Percentage of Subjects With INR Correction at Various Times After the End of Infusion
Time Frame: From the end of infusion until INR correction; calculated at 0.5, 1, 3, 6, 12, and 24 h after the end of infusion
|
The time taken from the end of infusion to INR correction (defined as an INR ≤ 1.3) is recorded.
The percentage of participants with INR correction at 0.5, 1, 3, 6, 12, and 24 h after the end of infusion is calculated.
|
From the end of infusion until INR correction; calculated at 0.5, 1, 3, 6, 12, and 24 h after the end of infusion
|
Percentage of Subjects Who Receive Red Blood Cells
Time Frame: From the start of infusion until 24 h after the start of infusion
|
Red blood cells are packed red blood cells (PRBCs).
|
From the start of infusion until 24 h after the start of infusion
|
Percentage of Subjects Who Receive Other Blood Products and Hemostatic Agents
Time Frame: From the start of infusion until 24 h after the start of infusion
|
Other blood products and hemostatic agents containing coagulation factors (such as whole blood, plasma, albumin, platelets) not including PRBCs.
|
From the start of infusion until 24 h after the start of infusion
|
Overall Treatment-emergent Adverse Events (TEAEs)
Time Frame: From the start of infusion up to the allowed time window of the Day 14 visit for non-serious AEs and from the start of infusion up to the allowed time window of the Day 45 visit for SAEs
|
Number of participants with TEAEs.
TEAEs are defined as adverse events that developed or worsened following exposure to investigational medicinal product.
Serious TEAEs are treatment-emergent serious adverse events (SAEs).
|
From the start of infusion up to the allowed time window of the Day 14 visit for non-serious AEs and from the start of infusion up to the allowed time window of the Day 45 visit for SAEs
|
Mean modified Rankin Scale for all subjects with intracranial haemorrhage
Time Frame: Before infusion and at Day 45
|
Before infusion and at Day 45
|
|
Mean Predicted and Actual Blood Loss (mls) for all Surgical/Invasive Procedures
Time Frame: From the start of surgery/procedure until the end of surgery/procedure
|
From the start of surgery/procedure until the end of surgery/procedure
|
|
Mean Volume (mls) of Wound Drainage for all Surgical/Invasive Procedures
Time Frame: From the start of wound drainage until the end of wound drainage, up to the final safety follow-up visit (Day 45)
|
From the start of wound drainage until the end of wound drainage, up to the final safety follow-up visit (Day 45)
|
|
Mean Time (mins) Between Last Suture and Cessation of Wound Drainage for all Surgical/Invasive Procedure
Time Frame: From the time of last suture until the end of wound drainage, up to the final safety follow-up visit (Day 45)
|
From the time of last suture until the end of wound drainage, up to the final safety follow-up visit (Day 45)
|
|
Vital signs
Time Frame: At baseline and until 24 hours after the end of infusion
|
Percentage of participants with a clinically significant change in vital signs (including blood pressure, respiratory rate, temperature and pulse rate)
|
At baseline and until 24 hours after the end of infusion
|
Viral serology
Time Frame: At baseline and until Day 45
|
Percentage of participants with negative viral serology (for Human immunodeficiency virus, Hepatitis B, Hepatitis A, Hepatitis C and Parvovirus B19) before infusion who become positive after infusion.
|
At baseline and until Day 45
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Program Director, Acquired Bleeding, CSL Behring
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (ACTUAL)
January 1, 2016
Study Completion (ACTUAL)
March 1, 2016
Study Registration Dates
First Submitted
October 27, 2014
First Submitted That Met QC Criteria
October 31, 2014
First Posted (ESTIMATE)
November 2, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
May 4, 2016
Last Update Submitted That Met QC Criteria
May 2, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BE1116_3004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Major Bleeding
-
OctapharmaRecruitingAcute Major BleedingUnited States, Bosnia and Herzegovina, Croatia, Spain, Georgia, Italy, Poland, Germany, Austria, Turkey, United Kingdom, Ukraine, France
-
AstraZenecaParexelRecruitingMajor BleedingUnited States, Japan, Germany
-
CSL BehringCompletedBlood Coagulation Disorders | Acute Major BleedingUnited States, Belarus, Bulgaria, Romania, Russian Federation, Ukraine
-
Sheba Medical CenterUnknownPlatlet Aggregation | Major Bleeding OutcomesIsrael
-
General Hospital of Shenyang Military RegionNot yet recruitingAcute Upper Gastrointestinal Bleeding | Acute Variceal Bleeding
-
Renmin Hospital of Wuhan UniversityNot yet recruitingAcute Variceal BleedingChina
-
Sofia RamströmEnrolling by invitation
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Variceal BleedingIndia
-
Chinese University of Hong KongBeijing Friendship Hospital; The First Affiliated Hospital of Soochow University and other collaboratorsCompletedAcute Upper Gastrointestinal Bleeding | Tumor BleedingHong Kong, China, Australia
-
Dayanand Medical College and HospitalCompletedAcute Gastroesophageal Variceal BleedingIndia
Clinical Trials on BE1116 (Prothrombin Complex Concentrate)
-
CSL BehringRecruitingTraumatic InjuryUnited States, United Kingdom, Australia
-
Baxalta now part of ShireBaxalta Innovations GmbH, now part of ShireCompletedHemophilia A or B With InhibitorsCroatia, North Macedonia, Ukraine
-
CSL BehringCompletedCoagulation Protein Disorders | Perioperative Care | Blood Loss, SurgicalUnited Kingdom
-
Rush University Medical CenterAdvocate Health CareCompleted
-
Tulane University School of MedicineCompletedHemophilia A With InhibitorsUnited States
-
CSL BehringCompletedAcquired Coagulation Factor DeficiencyAustria, Germany, Hungary, Israel, Lithuania, Netherlands, Poland, Switzerland
-
Konkuk University Medical CenterNot yet recruitingProstate Cancer | Hip Osteoarthritis | Knee Disease | Spine, Open
-
IRCCS Policlinico S. DonatoTerminatedBleeding | Surgery--Complications | Congenital Heart Disease | Transfusion-Related Acute Lung Injury | Cardiac Defect | Fibrinogenopenia; Acquired | Transfusion-Associated Circulatory OverloadItaly
-
Mayo ClinicWithdrawn